NASDAQ:TNXP

Tonix Pharmaceuticals Stock Forecast, Price & News

$0.72
-0.01 (-1.38 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.71
$0.73
50-Day Range
$0.70
$1.39
52-Week Range
$0.51
$2.12
Volume4.84 million shs
Average Volume8.47 million shs
Market Capitalization$235.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
30 days | 90 days | 365 days | Advanced Chart
Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Tonix Pharmaceuticals logo

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

420th out of 2,223 stocks

Pharmaceutical Preparations Industry

215th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

Is Tonix Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Tonix Pharmaceuticals?

Wall Street analysts have given Tonix Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tonix Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a decrease in short interest in July. As of July 15th, there was short interest totaling 11,660,000 shares, a decrease of 35.6% from the June 30th total of 18,110,000 shares. Based on an average trading volume of 10,450,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 3.5% of the company's shares are short sold.
View Tonix Pharmaceuticals' Short Interest
.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Tonix Pharmaceuticals
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its earnings results on Sunday, May, 9th. The company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01.
View Tonix Pharmaceuticals' earnings history
.

How has Tonix Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TNXP shares have decreased by 13.8% and is now trading at $0.7160.
View which stocks have been most impacted by COVID-19
.

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Tonix Pharmaceuticals shares reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for TNXP?

1 Wall Street analysts have issued 12 month target prices for Tonix Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 458.7% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 63, Pay $1.07M)
  • Mr. Bradley Saenger CPA, CPA, CFO & Treasurer (Age 47, Pay $586.16k)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 55, Pay $676.2k)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.
  • Dr. Herbert W. Harris, Exec. VP of Translational Medicine
  • Dr. Daniel J. Clauw, Consultant
  • Dr. R. Michael Gendreau, Consultant (Age 65)

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.06%). Company insiders that own Tonix Pharmaceuticals stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends for Tonix Pharmaceuticals
.

Which institutional investors are buying Tonix Pharmaceuticals stock?

TNXP stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell, and Seth Lederman.
View insider buying and selling activity for Tonix Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.72.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals has a market capitalization of $235.75 million. The company earns $-50,460,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals employs 26 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is www.tonixpharma.com.

Where are Tonix Pharmaceuticals' headquarters?

Tonix Pharmaceuticals is headquartered at 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.